Pharmaceuticals, Biotechnology and Life Sciences
— Additional Horizon data accepted as a poster presentation at ENDO 2020 summarize the first U.S.-based assessment of the GO-QOL…
Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include…
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of…
WILMINGTON, N.C.–(BUSINESS WIRE)–PPD, Inc. (Nasdaq:PPD) has been recognized for excellence in clinical research for the ninth consecutive year by pharmaceutical…
The results of this study provide evidence of the potential benefit of MK-6482 and support further investigation into how this HIF-2α inhibitor could play a meaningful role for these patients
– Approval is Based on Results of Phase 3 ECHELON-2 Trial, Which Demonstrated Treatment with ADCETRIS Plus CHP (cyclophosphamide, doxorubicin,…
SALT LAKE CITY–(BUSINESS WIRE)–Recursion, a digital biology company industrializing drug discovery, today announced it has entered into a global licensing…
– Approval Based on Positive ECHELON-2 Phase 3 Trial Results Demonstrating Superior Progression-Free Survival and Overall Survival with ADCETRIS plus…
ALACHUA, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of…
– MGTA-145 was shown to be a rapid, reliable, efficient and G-CSF-free method to obtain high numbers of functional HSCs…